Search

Your search keyword '"Baicchi, U"' showing total 143 results
Start Over Author "Baicchi, U"
143 results on '"Baicchi, U"'

6. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey

Author

Claudio, Velati, Luisa, Romano, Laura, Fomiatti, Lorella, Baruffi, Alessandro Remo Zanetti, Research Group: Sciariada, Simti L., Lobbiani, L., Prati, D., Marconi, M., Ravagnani, E., Rossi, E., Rossini, S., Bellavita, P., Moroni, G. A., Bodini, U., Pagliaro, P., Azzario, F., Rossi, D., Sciorelli, G., Salvaneschi, L., Cambie, G., Marini, M., Pizzoccolo, G., Gazzola, G. B., Peres, E., Mariottini, C., Graziani, G., Baicchi, U., Palla, P., Vacri, L., Strada, P., Miceli, M., Iudicone, P., Girelli, Gabriella, Ursitti, A., De Silvestro, G., Gentile, R., Di Paola, P., Manca, M., Martinelli, L., Bonomo, P., Calabrese, S., Pistolese, G., Aprili, G., Bressan, F., Ripamonti, M., Catalano, A., Gallerano, P., Giacalone, I., Fiorilla, A., Giannotti, G., Cantella, R., Di Persia, M. G., Esposito, V., Sardella, C., Di Monte, D., Bajorek, M., Reina, A., Silvani, C. M., Piani, M., Salvoni, G., De Felice, L., Macri, M., De Palma, M., Vecchi, C., Belloni, M., Bettini, C., Ghiazza, P., De Santis, D., Di Mauro, L., Antoncecchi, S., Rinaldi, C., Allegreita, G., Siracusano, L., Adami, R., Lanteri, M., Mazzei, C., Tagariello, G., Gajo, G. B., Berti, P., Giordano, C., Palazzesi, G., Del Gusto, B., Pavone, A., Vacchini, M., Tomasini, A., Vaselli, G., Fiorin, F., Bresolin, G., Bertola, F., Testa, D., Semino, G., Tomasini, I., Zucchelli, P., Chicchi, R., Peano, G., Franchi, D., Sabelli, M., Miloro, G., Di Gregorio, P., Reimondo, P., Cimino, G., Tripodi, G., Borzini, P., Tarditi, M., Cocchi, T., Pata, V., Santarelli, R., Geremicca, W., Minerva, A., Maccarione, F. P., Solanda, F., Rivasi, P., Carubia, F., Prinoth, O., Ostuni, A., Bossio, M., Maggiotto, A., Valentino, F., Puzzonia, P., and Source Musto, C.

Subjects
Adult, Male, Hepatitis B virus, Genotype, Hepacivirus, Hepatitis C virus, Immunology, Blood Donors, HIV Infections, medicine.disease_cause, Virus, Flaviviridae, Orthohepadnavirus, Risk Factors, Seroepidemiologic Studies, medicine, Humans, Mass Screening, Immunology and Allergy, Aged, biology, business.industry, HIV, virus diseases, Hematology, Middle Aged, Hepatitis B, biology.organism_classification, medicine.disease, Hepatitis C, Virology, digestive system diseases, Italy, Hepadnaviridae, Virus Diseases, Health Care Surveys, Blood Banks, Female, Morbidity, Safety, business, Risk Reduction Behavior
Abstract

BACKGROUND: Nucleic acid testing (NAT) for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has been implemented in several European countries and in the United States, while hepatitis B virus (HBV) NAT is still being questioned by opinions both in favor and against such an option, depending on the HBV endemicity, health care resources, and expected benefits. STUDY DESIGN AND METHODS: This survey was aimed to assess the NAT impact in improving the safety of blood supply in Italy, 6 years after implementation. The study involved 93 Italian transfusion centers and was carried out in 2001 through 2006. A total of 10,776,288 units were tested for the presence of HCV RNA, 7,932,430 for HIV RNA, and 3,405,497 for HBV DNA, respectively. RESULTS: Twenty-seven donations or 2.5 per million tested were HCV RNA–positive/anti-HCV–negative; 14 or 1.8 per million units tested were HIV RNA–positive/anti-HIV–negative; and 197 or 57.8 per million donations tested were HBV DNA–positive/hepatitis B surface antigen–negative. Of the latter, 8 (2.3/106) were collected from donors in the window phase of infection and 189 (55.5/106) from donors with occult HBV. Sixty-eight percent of the latter donors had hepatitis B surface antibody, 74.5 percent of whom with concentrations considered protective (≥10 mIU/mL). CONCLUSION: NAT implementation has improved blood safety by reducing the risk of entering 2.5 HCV and 1.8 HIV infectious units per million donations into the blood supply. The yield of NAT in detecting infectious blood before transfusion was higher for HBV than for HCV or HIV. However, the benefit of HBV NAT in terms of avoided HBV-related morbidity and mortality in blood recipients needs to be further evaluated.

Published
2008
Full Text
View/download PDF

13. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery

Author

Rizzo, Stanislao, Pellegrini, Maria Grazia, Benocci, F., Belting, C., Baicchi, U., Vispi, M., Rizzo S. (ORCID:0000-0001-6302-063X), Pellegrini G., Rizzo, Stanislao, Pellegrini, Maria Grazia, Benocci, F., Belting, C., Baicchi, U., Vispi, M., Rizzo S. (ORCID:0000-0001-6302-063X), and Pellegrini G.

Abstract

PURPOSE: To evaluate the safety and efficacy of intravitreal injection of autologous plasmin enzyme (APE) in inducing a posterior vitreous detachment (PVD). APE was obtained by a modified method 1 hour before surgery. METHODS: APE was obtained by centrifugation of autologous whole blood from the patients 1 hour before surgery and by incubation with streptokinase. APE was injected in the vitreous cavity 20 minutes before surgery. This procedure was applied for 20 patients who underwent vitrectomy for macular pucker, macular hole, and macular edema due to vitreoretinal traction. The status of PVD was graded intraoperatively. The plasmin concentration obtained by this method and the plasminogen titer of the plasma from each patient were compared. Activated partial thromboplastin time was controlled before surgery and 1, 6, 12, and 24 hours after surgery to evaluate alteration of the coagulation due to systemic absorption of the plasmin. RESULTS: Preparation of APE was easy and took on average 45 minutes for all patients. A PVD with an evident Weiss ring was observed during surgery in 17 eyes (85%). The average plasmin activity was 0.26 IU/0.2 mL activated plasma. The partial thromboplastin time did not show any alteration in any of the patients with respect to preoperative values. CONCLUSION: APE obtained by this method can lead to a PVD and facilitate the complete remotion of vitreous cortex. The intravitreal injection does not lead to alteration of systemic blood coagulation. Copyright © by Ophthalmic Communications Society, Inc.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results